Cargando…

Depression and Cognitive Impairment—Extrahepatic Manifestations of NAFLD and NASH

Non-alcoholic fatty liver disease (NAFLD) and its complication non-alcoholic steatohepatitis (NASH) are important causes of liver disease worldwide. Recently, a significant association between these hepatic diseases and different central nervous system (CNS) disorders has been observed in an increas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colognesi, Martina, Gabbia, Daniela, De Martin, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400092/ https://www.ncbi.nlm.nih.gov/pubmed/32708059 http://dx.doi.org/10.3390/biomedicines8070229

Ejemplares similares

NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations
por: Adinolfi, Luigi Elio, et al.
Publicado: (2016)

The Role of Oxidative Stress in NAFLD–NASH–HCC Transition—Focus on NADPH Oxidases
por: Gabbia, Daniela, et al.
Publicado: (2021)

A Nutraceutical Formulation Containing Brown Algae Reduces Hepatic Lipid Accumulation by Modulating Lipid Metabolism and Inflammation in Experimental Models of NAFLD and NASH
por: Gabbia, Daniela, et al.
Publicado: (2022)

Noninvasive Diagnosis of NAFLD and NASH
por: Piazzolla, Valeria Annarita, et al.
Publicado: (2020)

The role of the microbiome in NAFLD and NASH
por: Kolodziejczyk, Aleksandra A, et al.
Publicado: (2018)

Evolving Role for Pharmacotherapy in NAFLD/NASH
por: Attia, Suzanna L., et al.
Publicado: (2020)

Imaging biomarkers of NAFLD, NASH, and fibrosis
por: Ajmera, Veeral, et al.
Publicado: (2021)

The Metabolic Activation of Sofosbuvir Is Impaired in an Experimental Model of NAFLD
por: Gabbia, Daniela, et al.
Publicado: (2022)

HCV Extrahepatic Manifestations
por: Kuna, Lucija, et al.
Publicado: (2019)

Current and future pharmacological therapies for NAFLD/NASH
por: Sumida, Yoshio, et al.
Publicado: (2017)

Lifestyle modification in NAFLD/NASH: Facts and figures
por: Hallsworth, Kate, et al.
Publicado: (2019)

Natural History of NAFLD/NASH
por: Ekstedt, Mattias, et al.
Publicado: (2017)

Diet and exercise in NAFLD/NASH: Beyond the obvious
por: Semmler, Georg, et al.
Publicado: (2021)

Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH
por: Finan, Brian, et al.
Publicado: (2020)

Current Options and Future Directions for NAFLD and NASH Treatment
por: Zhang, Chunye, et al.
Publicado: (2021)

Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
por: Welch, Ryan D., et al.
Publicado: (2022)

Role of NLRP3 Inflammasome in the Progression of NAFLD to NASH
por: Wan, Xingyong, et al.
Publicado: (2016)

Deciphering the role of aberrant DNA methylation in NAFLD and NASH()
por: Vachher, Meenakshi, et al.
Publicado: (2022)

Extrahepatic Manifestations of Primary Biliary Cholangitis
por: Chalifoux, Sara L, et al.
Publicado: (2017)

A Systematic Review of NAFLD-Associated Extrahepatic Disorders in Youths
por: Pacifico, Lucia, et al.
Publicado: (2019)

Improved pathology reporting in NAFLD/NASH for clinical trials
por: Langford, Caitlin Rose, et al.
Publicado: (2022)

Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models
por: Mahmoudi, Ali, et al.
Publicado: (2022)

Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH
por: Svegliati-Baroni, Gianluca, et al.
Publicado: (2020)

Modeling Diet-Induced NAFLD and NASH in Rats: A Comprehensive Review
por: Carreres, Lydie, et al.
Publicado: (2021)

Remodeling of Mitochondrial Plasticity: The Key Switch from NAFLD/NASH to HCC
por: Longo, Miriam, et al.
Publicado: (2021)

Contribution of Metabolomics to the Understanding of NAFLD and NASH Syndromes: A Systematic Review
por: Piras, Cristina, et al.
Publicado: (2021)

Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives
por: Finotti, Michele, et al.
Publicado: (2021)

Dermatologic Extrahepatic Manifestations of Hepatitis C
por: Dedania, Bhavtosh, et al.
Publicado: (2015)

Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease
por: Li, Andrew A., et al.
Publicado: (2020)

Extrahepatic manifestations of hepatitis E virus: An overview
por: Fousekis, Fotios S., et al.
Publicado: (2020)

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD
por: Bazick, Jessica, et al.
Publicado: (2015)

Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Drescher, Hannah K., et al.
Publicado: (2019)

Involvement of Intracellular TAGE and the TAGE–RAGE–ROS Axis in the Onset and Progression of NAFLD/NASH
por: Sakasai-Sakai, Akiko, et al.
Publicado: (2023)

Recent updates on the role of the gut-liver axis in the pathogenesis of NAFLD/NASH, HCC, and beyond
por: Ohtani, Naoko, et al.
Publicado: (2023)

Activation of Kupffer cells in NAFLD and NASH: mechanisms and therapeutic interventions
por: Xu, Gao-Xin, et al.
Publicado: (2023)

Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH
por: Vilalta, Adrian, et al.
Publicado: (2022)

Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH
por: Hydes, Theresa J., et al.
Publicado: (2020)

Insights into the Impact of Microbiota in the Treatment of NAFLD/NASH and Its Potential as a Biomarker for Prognosis and Diagnosis
por: Plaza-Díaz, Julio, et al.
Publicado: (2021)

Metabolic Spectrum of Liver Failure in Type 2 Diabetes and Obesity: From NAFLD to NASH to HCC
por: Kim, Hyunmi, et al.
Publicado: (2021)

SAT-LB004 Therapeutic Potential of LPCN 1144 in NAFLD and NASH
por: Baker, Jonathan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6bl9eh8h2r5l8n9msh4kmu1l44